Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.148
+$0.0043 · +2.99%
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Previous close
$0.148
+$0.0043 · +2.99%
Regular session · ET · Market data may be delayed.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Day range
Current $0.148
52-week range
Current $0.148
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
54
Mixed
Risk
65
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Day range
Current $0.148
52-week range
Current $0.148
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 359.7K USD | 401K USD | 145.8K USD | 119.8K USD | 46K USD |
| Cost of goods sold | 23.84K USD | 28.07K USD | — | — | — |
| Gross profit | 335.86K USD | 372.93K USD | 145.8K USD | 119.8K USD | 46K USD |
| Research and development | 10.09M USD | 5.35M USD | 4.03M USD | 3.51M USD | 729.06K USD |
| Selling, general, and administrative | 5.89M USD | 6.58M USD | 11.33M USD | 15.58M USD | 25.62M USD |
| Operating expenses | 15.98M USD | 11.93M USD | 15.37M USD | 18.98M USD | 26.35M USD |
| Interest income | 266.21K USD | 616.08K USD | 552.29K USD | 11.65K USD | — |
| Interest expense | — | — | — | — | 1.82M USD |
| Depreciation and amortization | 209.99K USD | 189.06K USD | 165.74K USD | 120.55K USD | 89.11K USD |
| Operating income | −15.65M USD | −11.56M USD | −15.22M USD | −18.86M USD | −26.31M USD |
| Net income | −14.24M USD | −8.98M USD | −10.42M USD | −13.22M USD | −44.3M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock splitUpcoming | Sep 8, 2026 | 1:20 | — | — |
Stock split | Oct 27, 2021 | 1:4,000 | — | — |
Stock split | Jul 7, 2015 | 1:20 | — | — |
Stock split | Apr 15, 2013 | 1:50 | — | — |
Stock split | Mar 3, 2008 | 1:250 | — | — |
Effective Sep 8, 2026
1:20
Effective Oct 27, 2021
1:4,000
Effective Jul 7, 2015
1:20
Effective Apr 15, 2013
1:50
Effective Mar 3, 2008
1:250
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
